WO2007009389A3 - Derives de propanamide substitues, preparation et utilisation de ces derives - Google Patents

Derives de propanamide substitues, preparation et utilisation de ces derives Download PDF

Info

Publication number
WO2007009389A3
WO2007009389A3 PCT/CN2006/001784 CN2006001784W WO2007009389A3 WO 2007009389 A3 WO2007009389 A3 WO 2007009389A3 CN 2006001784 W CN2006001784 W CN 2006001784W WO 2007009389 A3 WO2007009389 A3 WO 2007009389A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
propanamide derivatives
substituted propanamide
substituted
derivatives
Prior art date
Application number
PCT/CN2006/001784
Other languages
English (en)
Chinese (zh)
Other versions
WO2007009389A2 (fr
Inventor
Mingwei Wang
Qing Liu
Caihong Zhou
Bin Wu
Xin Hui
Original Assignee
Shanghai Inst Materia Medica
Mingwei Wang
Qing Liu
Caihong Zhou
Bin Wu
Xin Hui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica, Mingwei Wang, Qing Liu, Caihong Zhou, Bin Wu, Xin Hui filed Critical Shanghai Inst Materia Medica
Publication of WO2007009389A2 publication Critical patent/WO2007009389A2/fr
Publication of WO2007009389A3 publication Critical patent/WO2007009389A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention se rapporte à des composés représentés par la formule (I), à leur préparation et à leur utilisation en tant qu'agoniste du récepteur Ϝ activé par les proliférateurs de peroxysomes (PPAR-Ϝ) dans le traitement du diabète et des complications diabétiques.
PCT/CN2006/001784 2005-07-22 2006-07-20 Derives de propanamide substitues, preparation et utilisation de ces derives WO2007009389A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100280554A CN100562514C (zh) 2005-07-22 2005-07-22 一类取代丙酰胺衍生物、其制备方法和用途
CN200510028055.4 2005-07-22

Publications (2)

Publication Number Publication Date
WO2007009389A2 WO2007009389A2 (fr) 2007-01-25
WO2007009389A3 true WO2007009389A3 (fr) 2007-04-19

Family

ID=37656077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/001784 WO2007009389A2 (fr) 2005-07-22 2006-07-20 Derives de propanamide substitues, preparation et utilisation de ces derives

Country Status (2)

Country Link
CN (1) CN100562514C (fr)
WO (1) WO2007009389A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2602248A1 (fr) 2011-12-05 2013-06-12 University Of Leicester Nouveaux composés pyrroliques
PT2797416T (pt) 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) * 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020072377A1 (fr) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
PT3880654T (pt) 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1434090A (en) * 1972-08-17 1976-04-28 Thomae Gmbh Dr K Halo-4-biphenylyl-butyric acid esters and amides and pharma ceutical compositions containing them
WO2004099150A2 (fr) * 2003-04-30 2004-11-18 Wyeth Derives d'amides et d'esters d'acide 2-cyanopropanoique et methodes d'utilisation desdits derives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1434090A (en) * 1972-08-17 1976-04-28 Thomae Gmbh Dr K Halo-4-biphenylyl-butyric acid esters and amides and pharma ceutical compositions containing them
WO2004099150A2 (fr) * 2003-04-30 2004-11-18 Wyeth Derives d'amides et d'esters d'acide 2-cyanopropanoique et methodes d'utilisation desdits derives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHIRAISHI T. ET AL.: "Specific Inhibitors of Tyrosine-Specific Protein Kinase. I. Synthesis and Inhibitory of alpha-Cyanocinnamamides", CHEM. PHARM. BULL, vol. 36, no. 3, 1988, pages 974 - 981 *
WELLS G. ET AL.: "Structural Studies on bioactive Compounds. 32. Oxidation of Tyrphostin Protein Tyrosine Kinase Inhibitors with Hypervalent Iodine Reagents", J. MED. CHEM., vol. 43, no. 8, 2000, pages 1550 - 1562, XP003010625 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin

Also Published As

Publication number Publication date
WO2007009389A2 (fr) 2007-01-25
CN100562514C (zh) 2009-11-25
CN1900054A (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
WO2007009389A3 (fr) Derives de propanamide substitues, preparation et utilisation de ces derives
WO2007003962A3 (fr) Agonistes de gpcr
WO2007003961A3 (fr) Agonistes de gpcr
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
WO2006127503A3 (fr) Composes, compositions pharmaceutiques et methodes d'utilisation de ces derniers dans le traitement des troubles du metabolisme
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
WO2007100535A3 (fr) Dérivés d'oxyntomoduline
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2007056681A3 (fr) Procedes d'administration d'agents hypoglycemiques
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2007056771A3 (fr) Composes destines au traitement de troubles metaboliques
MX2008002370A (es) Exendina para tratar la diabetes y reducir el peso del cuerpo.
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
CL2007002186A1 (es) Compuestos derivados espirocetal sustituidos de anillo fusionado; composicion farmaceutica que comprende a dicho compuesto; y uso de la composicion para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
WO2007022947A3 (fr) Composes 5-cycle-heteroaromates et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
WO2007145835A3 (fr) Dérivés de benzamide et utilisations associées à ceux-ci
PT1789403E (pt) Derivados de n-(fenil-oxazol-4-ilmetoximetil)-ciclo-hexilsuccinamida e compostos relacionados como ligandos dos ppar (receptores activados de proliferadores de peroxisomas) para o tratamento da hiperlipidemia e diabetes
WO2008053446A3 (fr) Composés de benzoxazépine, leur préparation et leur utilisation
WO2005118538A3 (fr) Arylsulfonamides et leurs utilisations
WO2010047592A3 (fr) Mélange conservateur et ses applications
WO2005097787A3 (fr) Derives de benzothiazoles capables de moduler l’activite des cdk et leur utilisation comme agents anticancereux
WO2006134499A3 (fr) Derives de 2-(1h-indolylsulfanyl)-aryl amine
TWI365741B (en) Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06761519

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06761519

Country of ref document: EP

Kind code of ref document: A2